Oligometastases Hypothesis to Advancing New Perspectives on Cancer: Oligo-Reurrence
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 15 August 2025 | Viewed by 784
Special Issue Editors
Interests: oligometastases; oligo-recurrence; sync-oligometastases; urological cancer; breast cancer; thoracic cancer; radiation oncology
Special Issues, Collections and Topics in MDPI journals
Interests: thoracic surgery; oligo-recurrence
Special Issues, Collections and Topics in MDPI journals
Interests: breast surgical oncology; clinical trials; translational research; oligo-recurrence
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The concept that has brought about the most significant change in clinical oncology in recent decades is oligometastases. Among these, the concept of oligo-recurrence, which is said to have a good prognostic subgroup among oligometastases, is the most important. Oligo-recurrence is a concept of recurrent cancer proposed by Niibe Y et al. in 2006.
Oligo-recurrence suggests that when the primary cancer tumor is controlled and 1–5 cases of recurrent or metastatic cancer occur, adding local therapy to systemic therapy may lead to long-term survival or even cure (in rare cases, only local treatment without systemic therapy).
In this Special Issue, we would like to use this as a place to discuss the basis for the fact that the concept of oligometastases is not a hypothesis and that oligo-recurrence is no longer a hypothesis.
We look forward to hearing from you.
Prof. Dr. Yuzuru Niibe
Dr. Dai Sonoda
Prof. Dr. Tadahiko Shien
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oligometastases
- oligo-recurrence
- sync-oligometastases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
